Defining a threshold for safe surgical management of vena cava thrombus in renal cell carcinoma patients: evidence from German total population data with 3,700 cases from 2006 to 2020 - Top-Institutions - MDSpire

Defining a threshold for safe surgical management of vena cava thrombus in renal cell carcinoma patients: evidence from German total population data with 3,700 cases from 2006 to 2020

  • By

  • Thomas Martin

  • Johannes Huber

  • Rainer Koch

  • Marius Butea-Bocu

  • Lennard Haak

  • Luka Flegar

  • Matthias Giese

  • Fabian Kormann

  • Cem Aksoy

  • Aristeidis Zacharis

  • Christer Groeben

  • November 29, 2024

  • 0 min

Share

Top Institutions in Urology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Urologic Oncology
    • Surgical Oncology
    • Vascular Surgery

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Urologic Oncology
    • Cardiothoracic Surgery
    • Vascular Surgery

  • #3

    University of Texas MD Anderson Cancer Center
    University of Texas MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Urologic Oncology
    • Surgical Oncology
    • Vascular Surgery

  • #4

    Charité – Universitätsmedizin Berlin
    Charité – Universitätsmedizin Berlin

    Berlin, Germany

    Key Differentiators

    • Urologic Oncology
    • Surgical Oncology
    • Vascular Surgery

  • #5

    University Hospital Heidelberg
    University Hospital Heidelberg

    Heidelberg, Germany

    Key Differentiators

    • Urologic Oncology
    • Surgical Oncology
    • Vascular Surgery

Original Source(s)

Defining a threshold for safe surgical management of vena cava thrombus in renal cell carcinoma patients: evidence from German total population data with 3,700 cases from 2006 to 2020

  • by Thomas Martin, Johannes Huber, Rainer Koch, Marius Butea-Bocu, Lennard Haak, Luka Flegar, Matthias Giese, Fabian Kormann, Cem Aksoy, Aristeidis Zacharis, Christer Groeben

  • November 29, 2024

Related Content

Validation of Clinical and Molecular Characteristics of the Highly Favorable IMDC Risk Category in Metastatic Renal Cell Carcinoma

Combination Immunotherapy Approaches in Metastatic Renal Cell Carcinoma with Favorable Risk Scores: A Meta-Analysis of Individual Patient Data

Endogenous Competition of circ_001024 for miR-145-3p: Implications for GLUT5 Regulation in Renal Cell Carcinoma